Van Belle P A, Elenitsas R, Satyamoorthy K, Wolfe J T, Guerry D, Schuchter L, Van Belle T J, Albelda S, Tahin P, Herlyn M, Elder D E
Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, and the Wistar Institute, USA.
Hum Pathol. 1999 May;30(5):562-7. doi: 10.1016/s0046-8177(99)90202-2.
The expression of the beta3 integrin subunit was investigated in 130 fixed, paraffin-embedded specimens of human melanomas and nevi using two different monoclonal antibodies. Expression was not observed in melanocytes and was absent or low in most nevi. In primary melanomas, expression was absent or low in the nontumorigenic radial growth phase, which includes the classes of in situ and microinvasive melanomas. In contrast, expression was high in the tumorigenic or vertical growth phase compartment of many primary melanomas and in most metastatic melanomas. Expression patterns were similar with the two antibodies, SSA6 and SAP, and was membrane-related as well as cytoplasmically expressed. In those nevi that reacted focally, the reactivity tended to occur in the dermal component of neurotized nevi, and in Spitz nevi, where the reactivity was stronger and more diffuse. A few dysplastic nevi showed focal reactivity of the junctional component. These results are consistent with tumor progression-related expression of the beta3 integrin, which is expressed in melanocytic tumors as the alphavbeta3 integrin, having affinity for matrix molecules, including vitronectin and fibronectin. In all melanomas, and in the subset of tumorigenic vertical growth phase melanomas, expression increased with thickness (P < .01). For this reason, and because ligation of this integrin has been shown in vitro to have several properties that may be related to the malignant phenotype, it is likely that expression of this marker may have prognostic value. However, because of its consistent and strong expression in Spitz nevi, the diagnostic utility of this marker will likely be limited.
使用两种不同的单克隆抗体，对130例人黑色素瘤和痣的固定石蜡包埋标本进行了β3整合素亚基表达的研究。在黑素细胞中未观察到表达，且大多数痣中表达缺失或较低。在原发性黑色素瘤中，在非致瘤性的放射状生长期（包括原位和微侵袭性黑色素瘤类别）中表达缺失或较低。相反，在许多原发性黑色素瘤的致瘤性或垂直生长期部分以及大多数转移性黑色素瘤中表达较高。两种抗体SSA6和SAP的表达模式相似，且与膜相关并在细胞质中表达。在那些有局灶性反应的痣中，反应性倾向于出现在神经化痣的真皮成分中，以及在Spitz痣中，后者的反应性更强且更弥漫。一些发育异常痣显示交界成分有局灶性反应。这些结果与β3整合素的肿瘤进展相关表达一致，β3整合素在黑素细胞肿瘤中作为αvβ3整合素表达，对包括玻连蛋白和纤连蛋白在内的基质分子具有亲和力。在所有黑色素瘤以及致瘤性垂直生长期黑色素瘤亚组中，表达随厚度增加（P <.01）。因此，并且因为在体外已显示该整合素的连接具有几种可能与恶性表型相关的特性，所以该标志物的表达可能具有预后价值。然而，由于其在Spitz痣中持续且强烈的表达，该标志物的诊断效用可能会受到限制。
